Home › Therapeutic areas › Hematology

Hematology (20 companies · 12 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Hematology Lead stage Mkt cap Programs
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 4 Approved $1.79B 7
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 1 Phase 2 $161M 6
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $662M 6
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.14B 6
CLYM Climb Bio HematologyImmunology+1 Rare 1 Phase 2 $574M 8
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $4.85B 7
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 2 NDA Submitted $602M 10
IRON Disc Medicine GI/HepatologyHematology+2 Rare 2 Phase 3 $3.49B 9
FBIO Fortress Biotech DermatologyHematology+4 Rare 1 Approved $61.4M 16
IMMX Immix Biopharma Hematology Rare 1 Phase 1 $603M 1
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 3 Approved $4.49B 29
NVCT Nuvectis Pharma HematologyOncology+1 Rare 1 Phase 3 $660M 9
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.04B 6
PRLD Prelude Therapeutics HematologyOncology Rare 1 Phase 1 $266M 3
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.14B 12
QURE uniQure HematologyMetabolic+1 Rare 1 Approved $1.46B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $69.4M 9